ADRIAMYCIN CARDIOMYOPATHY - PATHOPHYSIOLOGY AND PREVENTION

Current knowledge about adriamycin cardiomyopathy indicates that the m ajor cause of this condition is increased oxidative stress although th e drug's antitumor action in patients may involve other mechanisms, Co ntroversies about the different antioxidants in preventing cardiomyopa thy likely stem from the fact that antioxidants must be effective in b oth the lipid and water phases, and the dose must be optimal, in order to be protective, Probucol, an antioxidant and promoter of endogenous antioxidants, is one such agent, Conducting clinical trials with an o ptimal dose of probucol is the next step and should make this great an ticancer drug safer and more efficient in the fight against the cancer .